# Renal Adjuvant MultiPle Arm Randomised Trial

> **NCT03288532** · PHASE3 · RECRUITING · sponsor: **University College, London** · enrollment: 1750 (estimated)

## Conditions studied

- Renal Cell Carcinoma

## Interventions

- **DRUG:** Durvalumab
- **DRUG:** Tremelimumab

## Key facts

- **NCT ID:** NCT03288532
- **Lead sponsor:** University College, London
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2018-07-19
- **Primary completion:** 2024-07-01
- **Final completion:** 2034-12-01
- **Target enrollment:** 1750 (ESTIMATED)
- **Last updated:** 2020-09-07

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03288532

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03288532, "Renal Adjuvant MultiPle Arm Randomised Trial". Retrieved via AI Analytics 2026-05-22 from https://api.ai-analytics.org/clinical/NCT03288532. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*